- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 215/36 - Atomes de soufre
Détention brevets de la classe C07D 215/36
Brevets de cette classe: 302
Historique des publications depuis 10 ans
|
18
|
23
|
29
|
24
|
21
|
14
|
24
|
19
|
10
|
6
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Agios Pharmaceuticals, Inc | 224 |
15 |
| Amgen Inc. | 4427 |
12 |
| Novartis AG | 10262 |
8 |
| Bristol-myers Squibb Company | 4742 |
8 |
| Hinova Pharmaceuticals Inc. | 102 |
7 |
| Jiangsu Hengrui Medicine Co., Ltd. | 692 |
6 |
| Oxford Drug Design Limited | 11 |
6 |
| Pharmaxis Ltd | 32 |
5 |
| Monsanto Technology LLC | 8568 |
4 |
| Galapagos NV | 234 |
4 |
| Galderma Research & Development | 351 |
4 |
| Korea Research Institute of Chemical Technology | 1469 |
4 |
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 178 |
4 |
| Southern Research Institute | 204 |
4 |
| The United States Government AS represented by The Department of Veterans Affairs | 1329 |
4 |
| The University of Melbourne | 569 |
4 |
| The University of Queensland | 661 |
4 |
| Inflazome Limited | 84 |
4 |
| AbbVie Global Enterprises Ltd. | 26 |
4 |
| Merck Patent GmbH | 5728 |
3 |
| Autres propriétaires | 188 |